Jean (Hoffman) Hoffman-Censits, MD, Oncology, Baltimore, MD, Johns Hopkins Hospital


Oncology Baltimore, MD

Genitourinary Oncology, Hematologic Oncology

Assistant Professor, Medical Oncology, Jefferson Medical College-Thos Jefferson Univ

Dr. Hoffman-Censits is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hoffman-Censits' full profile

Already have an account?

Education & Training

  • Fox Chase Cancer Center
    Fox Chase Cancer CenterFELLOWSHIP
  • Thomas Jefferson University
    Thomas Jefferson UniversityRESIDENCY
  • Sidney Kimmel Medical College
    Sidney Kimmel Medical CollegeMEDICAL_SCHOOL
  • Trinity CollegeOTHER_TRAINING

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2018 - 2022
  • DC State Medical License
    DC State Medical License 2018 - 2020
  • DE State Medical License
    DE State Medical License 2017 - 2019
  • NJ State Medical License
    NJ State Medical License 2017 - 2019
  • PA State Medical License
    PA State Medical License 2002 - 2018
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2011-2013
  • Senior Achievement Award National Alumni Association, 1995
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies  
    Dan TD, Eldredge-Hindy HB, Hoffman-Censits, J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB, Am J Clin Oncol, 1/25/2015
  • Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma  
    Hoffman-Censits, J. and Wong, Y, Clin Genitourin Cancer, 1/1/2015
  • Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based chemotherapy in Muscle-invasive Bladder Cancer  
    Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, V..., Eur Urol, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Join now to see all


  • Neoadjuvant chemotherapy (NAC) has no adverse effect on radical cystectomy (RC) or perioperative complications.
    Haseebuddin,M., Mehrazin, R., Trabulsi, E., Devarajan, K., Wong, Y., Hoffman-Censits, J., Lallas, C., Viterbo, R., Kutikov, A., Smaldone, M., Greenberg, R., Uzzo, R...., Journal of Urology; Society of Urologic Oncology Meeting Abstracts, 1/1/2015
  • Phase I trial of weekly cabazitaxel with concurrent intensity-modulated radiation therapy (IMRT) and androgen deprivation therapy (ADT) for the treatment of high-risk ...
    Jianqing Lin, Robert Benjamin Den, Timothy Norman Showalter, Jean H. Hoffman-Censits, Monica McGuire, Brooke Kennedy, Mark Hurwitz, Edouard John Trabulsi, Costas D. La..., ASCO GU Meeting Abstracts, 1/1/2015
  • Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.
    Plimack ER, Dunbrack R, Brennan T, Andrake M, Zhou Y, Serebriiskii I, Dulaimi E, Hoffman-Censits J, Bilusic M, Wong Y, Kutikov A, Viterbo R, Greenberg RE, Chen D, Lall..., ASCO GU Meeting Abstracts, 1/1/2015
  • Join now to see all


  • Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Bladder Cancer – evolving paradigms and immunotherapy. 
    Albert Einstein Medical Center, Philadelphia, PA - 1/1/2015
  • Update on Clinical Trials in Urothelial Carcinomas 
    King of Prussia, PA - 1/1/2015
  • Join now to see all

Press Mentions

  • Improved Patient Selection Needed to Optimize Expanding Options in Bladder Cancer
    Improved Patient Selection Needed to Optimize Expanding Options in Bladder CancerOctober 27, 2017
  • Atezolizumab Update Affirms Activity in Bladder Cancer
    Atezolizumab Update Affirms Activity in Bladder CancerJanuary 09, 2016

Hospital Affiliations